{"cord_uid":"rbye73yv", "sourcedb":"PMC", "sourceid":"PMC6567157", "divid":24, "text":"The remaining vaccine candidates are all in the stages of preclinical or laboratory development and invariably target the S glycoprotein or RBD critical for viral entry ( Table 2) . Vaccines based on inactivated [62, 63] or virus-like particles [64] have historical precedence in inducing protective immune responses in humans. Whether the same strategies are applicable to MERS-CoV requires further studies, particularly when it comes to possible safety concerns [62] .", "project":"cdlai_CORD-19", "denotations":[]}